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A B S T R A C T
Multiple interactions between the immune system and sleep are known, including the eﬀects of microbial
challenge on sleep or the eﬀects of sleep loss on facets of the immune response. Cytokines regulate, in part, sleep
and immune responses. Here we examine the role of an anti-inﬂammatory cytokine, interleukin-37 (IL-37) on
sleep in a mouse strain that expresses human IL-37b (IL37tg mice). Constitutive expression of the IL-37 gene in
the brains of these mice under resting conditions is low; however, upon an inﬂammatory stimulus, expression
increases dramatically. We measured sleep in three conditions; (a) under baseline conditions and after 6 h of
sleep loss, (b) after bolus intraperitoneal administration of lipopolysaccharide (LPS) or IL-1β and (c) after
intranasal inﬂuenza virus challenge. Under baseline conditions, the IL37tg mice had 7% more spontaneous non-
rapid eye movement sleep (NREMS) during the light period than wild-type (WT) mice. After sleep deprivation
both WT mice and IL37tg mice slept an extra 21% and 12%, respectively, during the ﬁrst 6 h of recovery.
NREMS responses after sleep deprivation did not signiﬁcantly diﬀer between WT mice and IL37tg mice.
However, in response to either IL-1β or LPS, the increases in time spent in NREMS were about four-fold greater
in the WT mice than in the IL37tg mice. In contrast, in response to a low dose of mouse-adapted H1N1
inﬂuenza virus, sleep responses developed slowly over the 6 day recording period. By day 6, NREMS increased
by 10% and REMS increased by 18% in the IL37tg mice compared to the WT mice. Further, by day 4 IL37tg
mice lost less weight, remained more active, and retained their body temperatures closer to baseline values than
WT mice. We conclude that conditions that promote IL-37 expression attenuate morbidity to severe
inﬂammatory challenge.
1. Introduction
Cytokine involvement in sleep regulation is extensively character-
ized (reviewed Imeri and Opp, 2009; Krueger, 2008; Krueger et al.,
2008; Mullington et al., 2010; Simpson and Dinges, 2007; Zielinski and
Krueger, 2011). Interleukin-1β (IL-1β) and tumor necrosis factor α
(TNFα) are pro-inﬂammatory sleep regulatory cytokines, although
several other cytokines, including anti-inﬂammatory cytokines, are
implicated in sleep-wake regulation. Injections of low doses of IL-1β
promote sleep; in contrast high doses inhibit sleep (Opp et al., 1991).
Similarly, even low doses of TNFα promote a sleep-like state in vitro
whereas high doses disrupt neuronal action potential patterns in co-
cultures of neurons and glia (Jewett et al., 2015). Sleep deprivation
(Taishi et al., 1998; 1999), stimulation of aﬀerent neurons (Churchill
et al., 2008; Hallett et al., 2010) or optogenetic stimulation of neurons
in culture (Jewett et al., 2015) up-regulate several brain cytokines
including IL-1β and TNFα (reviewed Krueger, 2008). Localized sleep
intensity, as determined from the amplitude of electroencephalogram
(EEG) slow waves (0.5–4 Hz), is enhanced by local application of IL-1β
or TNFα or locally enhanced neuronal activity (Yasuda et al., 2005;
Yoshida et al., 2004; Kattler et al., 1994). Conversely, inhibition of
cortical TNFα expression inhibits local sleep intensity (Yoshida et al.,
2004).
Microbial infections or systemic or central administration of
various microbial products enhances sleep and these responses are
associated with pro-inﬂammatory/pro-somnogenic cytokine expres-
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sions (reviewed Majde and Krueger, 2005). Inﬂuenza virus infections
in mice are accompanied by changes in sleep and multiple cytokines
(Alt et al., 2007; Chen et al., 2004; Fang et al., 1995; Jhaveri et al.,
2006; Kapás et al., 2008; Lupfer et al., 2013). In mice, deﬁciency of a
speciﬁc cytokine involved in the responses to inﬂuenza virus alters the
sleep and morbidity responses to the virus (Alt et al., 2007; Chen et al.,
2004; Davis et al., 2015; Traynor et al., 2007). Systemic or central
administration of lipopolysaccharide (LPS) also can enhance sleep
(Toth and Opp, 2001). Similar to the dose-dependent eﬀects of bolus
injections of IL-1β or TNFα, or severe infections, high doses of LPS
induce sleep fragmentation suggesting that these eﬀects are the result
of stimulating high levels of pro-inﬂammatory cytokines (Bettis et al.,
2006; Lundkvist et al., 2004; Olivadoti and Opp, 2008; Morrow and
Opp, 2005).
The dose-dependencies of the direction of eﬀects induced by IL-1β
or TNFα suggest negative feedback steps are engaged. Anti-somnogenic
cytokines such as IL-4 (Kushikata et al., 1998) and IL-10 (Opp et al.,
1995) are less well studied, although their actions on sleep are
generally inhibitory. Further, the IL-1 receptor antagonist (Takahashi
et al., 1997), as well as cytokine soluble receptors, e.g. the TNF soluble
receptor (Takahashi et al., 1995) inhibit sleep. Collectively, the sleep
responses to pro- and anti-inﬂammatory cytokines and those in
response to infectious challenge or speciﬁc microbial products indicate
the involvement of the cytokine network in sleep regulation whether in
health or disease.
IL-37b (hereafter called IL-37) is one of 5 isoforms of the IL-1
family of cytokines, formerly called IL-1F7 (Dinarello, 2010; Dinarello
et al., 2016; Smith et al., 2000). IL-37 is up-regulated by microbial
products, TNFα, IL-1β, IL-18 (Nold et al., 2010). Recombinant IL-37
reduces the production of several pro-inﬂammatory, pro-somnogenic
cytokines including TNFα, IL-1β, and IL-6, while sparing anti-inﬂam-
matory/anti-somnogenic cytokines, e.g. IL-10 and the IL-1 receptor
antagonist (Nold et al., 2010, Sharma et al., 2008). Such feedback
actions result in a dampening of pro-inﬂammatory responses (the
cytokine storm), although the dynamics of such actions are complex
and understudied. Humans express IL-37 in various tissues including
the brain (Pan et al., 2001). A role for IL-37-driven cytokine regulation
is demonstrated in multiple pathologies including microbial infections
(Fujita et al., 2013; Imaeda et al., 2013; Li et al., 2013a, 2013b;
McNamee et al., 2011; Pei et al., 2013, Teng et al., 2014). The mouse
IL-37 homologue has not been found (Taylor et al., 2002) and the IL-
37 gene is also not present in chimpanzees (Newman et al., 2005).
Human cell lines and mouse macrophages transfected with IL-37 have
attenuated pro-inﬂammatory cytokine responses to LPS. A transgenic
mouse strain expressing human IL-37 (IL37tg) exhibits attenuated
pro-inﬂammatory cytokine levels in response to LPS (Nold et al., 2010)
and dextran sulfate sodium-induced colitis (McNamee et al., 2011).
However, in the absence of cytokine or microbial stimulation, IL-37
expression is low in the IL37tg mice (Nold et al., 2010). Similarly, in
pilot studies we found that IL-37 mRNA was not detected in WT mice.
Further, IL-37 mRNA was detectable in IL37tg mice in the somato-
sensory cortex and liver following sleep deprivation or LPS treatment.
Although the IL-37 gene is absent in WT mice, the IL37tg line has
contributed to the mechanistic understanding of immune responses
(Bulau et al., 2014; Coll-Miro et al., 2016; Dinarello et al., 2016;
McNamee et al., 2011; Luo et al., 2014; Nold et al., 2010; Nold-Petry
et al., 2015) and provides a unique model to examine pro- and anti-
inﬂammatory signaling in sleep responses to inﬂammatory challenges.
Here we describe the eﬀects of the presence of the IL-37 gene in mice
on sleep. Three distinct conditions were examined. First, we deter-
mined spontaneous sleep and sleep responses to mild sleep loss in
otherwise unchallenged mice; the presence of IL-37 had little eﬀect on
mouse sleep in these conditions. Second, we challenged the IL37tg
mice with bolus injections of somnogenic doses of IL-1β or LPS; the
anticipated sleep responses to these substances were greatly attenu-
ated. Third, we determined sleep responses to a more pernicious
stimulus, inﬂuenza virus challenge; in this case the presence of IL-37
enhanced sleep responses and simultaneously reduced morbidity. We
conclude that IL-37 plays a central, albeit complex, role in attenuating
severe inﬂammatory challenge.
2. Methods
2.1. Animals and surgery
Male mice (8–10 weeks old) expressing human IL-37 isoform b
precursor transgene on a C57BL6 mouse background were locally bred
as homozygotes for 8 generations. As previously described (Nold et al.,
2010), fertilized eggs of C57BL/6 mice were injected with an IL-37b
pIRES plasmid driven by a CMV promoter and contained a GFP
expression sequence and a FLAGged C terminus. The eggs were
subsequently implanted into C57BL6 females after which male foun-
ders mated C57BL6 WT females. A separate colony of C57BL6, WT
mice (Jackson Laboratories, Sacramento, CA) were bred in our
vivarium and served as controls. Mice were individually housed in
sound-attenuated environmental chambers, maintained on a 12:12 h
light:dark cycle (light onset=ZT0), at 23 ± 2 °C and provided food and
water ad libitum. Mice used for polysomnographic analyses were
implanted with electroencephalogram (EEG) electrodes over the right
and left parietal cortices (1 mm caudal of bregma and either ± 2 mm
lateral of bregma) and a ground electrode over the cerebellum
(−0.5 mm caudal of lambda; Franklin and Paxinos, 2007). An electro-
myogram (EMG) electrode was placed in the nuchal muscles.
Ketamine-xylazine (87 and 13 mg/kg, respectively) anesthesia was
used for surgical procedures as previously described (Davis et al.,
2015). Electrodes were mounted onto the skulls with dental cement
and the mice were tethered to ampliﬁers using wire cables. Mice were
allowed at least 7 days of recovery from surgery before use. Separate
mice were surgically implanted with temperature and activity tracking
transponders (TAE-mitters, Mini Mitter, Bend, OR) intraperitoneally
under ketamine/xylazine anesthesia and allowed at least 1 week of
recovery prior to the experiment. At the conclusion of each experiment
mice were euthanized, tails collected and genotypes conﬁrmed by
Transnetyx Inc. (Cordova, TN). All experimental protocols were
approved by the Washington State University Animal Care and Use
Committee and were in compliance with National Institutes of Health
Oﬃce of Laboratory Animal Welfare guidelines.
2.2. Sleep, temperature and activity recording analyses
Analog EEG (ﬁltered below 0.1 Hz and above 100 Hz with a 60 Hz
notch ﬁlter) and EMG ampliﬁed signals were digitized at 128 Hz and
recorded to the local hard drive. Sleep analyses were conducted using
Sleep Sign Software (Kissei Comtec Co., Ltd, Japan). EEG wave forms
and EMG amplitudes, which reﬂect brain and muscle activity respec-
tively, are characteristic properties of sleep states in mammals and
birds. NREMS, REMS, and waking vigilance states were determined
manually oﬀ-line in 10 s epochs as previously described (Davis et al.,
2015). NREMS was identiﬁed by high-amplitude EEG signals and low
EMG activity. Regular low-amplitude EEG and minimal EMG activity
characterized REMS. Wake periods were recognized by low amplitude
fast EEG and high EMG activity. Because mice are mostly active during
the dark phase and sleep most of the time during daylight hours,
vigilance state durations were calculated in 12 h blocks corresponding
to the light (ZT0-12) and dark (ZT12-0) periods. Another measure
often used to determine the depth (intensity) of NREMS is the
amplitude of EEG slow waves. Although EEG delta wave (0.5–
4.0 Hz) amplitudes are regulated independently from duration of sleep,
during normal sleep the two measures correlate with each other (Davis
et al. 2011). Fast Fourier transformations of Hanning ﬁltered EEG
signals (µV2) of each artifact free epoch were used to calculate NREMS
EEG delta power [0.5–4 Hz range; also known as slow-wave activity
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(SWA)] and NREMS EEG power spectra in 1 Hz bins in the frequency
range of 0–20 Hz for the 12 h light and/or dark period or the ZT6-12
after sleep deprivation (SD). SWA for each 12 h bin was normalized
using the 24 h mean of the state-speciﬁc baseline value for each
individual mouse (Davis et al., 2015).
For the Mini Mitter implanted mice, telemetric signals were
recorded at 6 min intervals using VitalView analysis software (Mini
Mitter, Bend, OR), and data points were derived from those values or
were averaged over 6 or 24 h bins for body temperature and locomotor
activity. Activity counts were normalized for each mouse by dividing
the averaged value by its total 24 h baseline activity count and are
expressed as a percent of baseline. Baseline was recorded for 24 h
beginning at ZT0 and continued for 7 days after infection.
2.3. Virus puriﬁcation and titration
A mouse-adapted H1N1 A/Puerto Rico/8/34 H1N1 (PR8) inﬂuen-
za virus (lot # 3×010621) was suspended in pyrogen-free allantoic ﬂuid
(Speciﬁc Pathogen-Free Avian Supply, North Franklin, CT) and iso-
lated by ultracentrifugation sucrose-gradient sedimentation as pre-
viously described (Grimm et al., 2007; Majde et al., 2010). The virus
was diluted to a protein concentration of 200 µg/ml, aliquoted, frozen
on dry ice, and stored at −80°C. A standard hemagglutination assay
with two-fold dilutions of puriﬁed PR8 (10 µl) mixed with 50 µl chicken
red blood cells and incubated at room temperature for 30 min yielded
1×107 virus particles/ml. Samples were tested for endotoxin levels
using a Limulus lysate gel-clot assay (Biowhittaker, Walkersville, MD);
endotoxin was below detection levels. Additionally, the puriﬁed virus
was negative for mycoplasma and acholeplasma contamination deter-
mined by nested PCR. In Madin–Darby canine kidney (MDCK) cells
(American Type Culture Collection, Manassas, VA), viral titrations
were assessed and expressed as median tissue culture infectious doses
(TCID50) as previously described (Grimm et al., 2007). The starting
titer of puriﬁed PR8 virus was 2.5×104 TCID50/ml.
2.4. Experiment 1: Spontaneous sleep and sleep responses to sleep
deprivation
WT (n=24) and IL37tg (n=23) mice were acclimated to the
experimental chambers and instrumentation for 2 days before record-
ing a 24 h baseline ZT 0-0. A separate group of mice were subjected to
gentle handling SD as previously described (Davis et al., 2015). Brieﬂy,
mice were kept awake in their home cages by gently disturbing the
bedding next to the animal or stroking the mouse with a brush when
behavioral indications of sleep were observed. After at least 7 days of
recovery from surgery and two days to acclimate to the EEG tethered
connection, baseline control recordings (ad libitum sleep) were taken
from IL37tg (n=9) and WT (n=7) mice for 24 h. After the baseline day,
mice were SD for 6 h after light onset (ZT0-6). EEG and EMG were
recorded for the next 18 h beginning immediately after the cessation of
SD (ZT 6-0).
2.5. Experiment 2: Sleep responses to systemic LPS and IL-1β
WT and IL37tg mice were provided with EEG and EMG electrodes
as above. After recovery from surgery, baseline data were obtained
from both strains for 24 h after an IP injection of saline (0.2 mL/
mouse) as a vehicle control. After the control recording period, IL37tg
and WT (n=7/strain) mice received IP injections of IL-1β (180 ng in
0.2 mL saline) and EEG and EMG were recorded for the next 24 h.
Separate WT and IL37tg mice, also provided with EEG and EMG
electrodes and allowed to recover from surgery, received an IP control
injection of saline (0.2 mL) at dark onset and baseline EEG and EMG
were recorded for 24 h. IL37tg and WT mice (n=8/strain) then
received an IP injection of LPS (500 ng in 0.2 mL saline) and EEG
and EMG were recorded for 24 h thereafter.
2.6. Experiment 3: EEG responses to inﬂuenza challenge
WT (n=12) and IL37tg (n=10) mice received 12.5 TCID50 of
puriﬁed mouse-adapted PR8 inﬂuenza virus. The live virus delivery
occurred by intranasal instillation of 50 µL of puriﬁed PR8, 25 µL per
nostril, under 20% isoﬂurane/80% polyethylene glycol (isoﬂurane-
PEG) anesthesia (Zielinski et al., 2013). The intranasal virus was given
within 1 h from light onset (ZT0-1). After viral challenge, mice were
placed back in their recording chambers and EEG and EMG were
recorded for the next 6 days. Prior studies (Davis et al., 2015) using the
12.5 TCID50 dose indicate that WT mice show morbidity (e.g. lower
weights, activity, temperature and enhanced NREMS amounts) on PI
Day 3 and begin dying on PI Day 7. Thus, PI Days 2, 4 and 6 were
selected for analyses.
2.7. Experiment 4: Core body temperature, activity and body weight
after inﬂuenza challenge.
IL37tg and WT mice (n=9/strain) were housed individually in their
home cages and placed on receiver plates and acclimated to the
recording chamber for at least one week after surgery before recording
a 24 h baseline for temperature and activity. Next, mice were infected
using the same technique and dose described in Experiment 3,
returned to their cages and recordings ensued for the next 7 days.
Body weights were taken prior to infection and on subsequent days at
ZT0.
3. Statistics
SPSS v.17 was used to analyze time spent in NREMS, REMS,
NREMS EEG SWA, locomotor activity, body temperature and weight
during the light and dark periods. Mixed two-way ANOVAs with a
within-subjects factor of treatment (baseline vs. post sleep deprivation;
saline vs. post-injection day 1) and between-subjects factor of strain
(WT vs. IL37tg). For the virus experiments a third factor of day (post
infection (PI) days 2, 4 and 6 or days 1–7) was added to the model. For
the 0–20 Hz power spectra mixed three-way ANOVAs were used to
analyze treatment in the 12 h light and dark periods or the 2 h post-IL-
1β or LPS injection periods (ZT12-14) with the additional within-
subjects factor of spectral frequency in 1 Hz bins. Outliers were
excluded based on a > 2 standard deviation criterion. A Huynh–Feldt
adjustment was used to mitigate sphericity violations of the repeated
measures, however the unadjusted degrees of freedom are reported for
clarity. Post hoc analyses were performed when main eﬀects or
interactions were signiﬁcant. Additionally, time- or frequency-matched
pairwise comparisons were made using independent- or paired-sam-
ples t-tests where p < 0.05 was considered signiﬁcant.
4. Results
4.1. Experiment 1: Spontaneous sleep and sleep responses to sleep
deprivation
IL37tg mice had 25 min more NREMS during the light period than
WTmice [Fig. 1A; t(45)=−2.79, p < 0.01]. Most of the increased NREMS
in IL37tg mice occurred during ZT4-12 (2 h data not shown). Baseline
REMS (Fig. 1B), NREMS EEG SWA (Fig. 1C), or NREMS spectral
power (Fig. 1D) were not diﬀerent between strains during the light or
dark periods.
During the 6 h after SD (ZT6-12) WT mice had 33 min more
NREMS compared to baseline while IL37tg mice had 21 min more
[Fig. 1E; Treatment: F(1,14)=37.97, p < 0.001]. NREMS durations were
not diﬀerent between strains and the extra NREMS in the subsequent
12 h dark period (ZT12-0) was not diﬀerent from baseline in either
strain. After SD, REMS rebounds occurred during the light and dark
periods [Fig. 1F; Treatment: F(1,14)=31.50, p < 0.001 and F(1,14)=30.13,
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p < 0.001, respectively] in both strains, but REMS rebounds were not
diﬀerent between strains. NREMS EEG SWA in ZT6-12 or in ZT12-0
was not signiﬁcantly diﬀerent from baseline or between strains nor was
NREMS EEG spectral power.
4.2. Experiment 2: Sleep responses to systemic LPS and IL-1β
Time in NREMS increased during the ﬁrst 12 h post-injection (dark
period) after IL-1β (180 ng) [Fig. 2A; Treatment: F(1,12)=28.53, p <
0.001]. Further, after IL-1β the IL37tg mice spent less time in NREMS
compared to WT mice [Strain: F(1,12)=9.23, p < 0.01]. Changes in
REMS amounts were not statistically signiﬁcant after IL-1β (Fig. 2B).
NREMS spectral power in the 2–5 Hz frequency band during the initial
2 h post-injection period (ZT12-14) was decreased in WT mice, while
spectral power in the 1–20 Hz frequency was not diﬀerent in IL37tg
mice [Fig. 2C; Treatment×Strain×Hz: F(19,228)=4.51, p < 0.001]. No
strain diﬀerences on any other sleep response measures were detected
during the IL-1β post-injection dark or light periods.
In the ﬁrst 12 h post-injection (dark period), NREMS duration
increased in both strains after LPS (500 ng) [Fig. 2D; Treatment:
F(1,14)=29.31, p < 0.001]. After LPS, however, the NREMS increase in
the IL37tg mice was substantially less than in WT mice [Strain:
F(1,14)=10.38, p < 0.01]. Further, during the light period 12–24 h after
LPS injection, IL37tg mice continued to have less NREMS [Strain:
F(1,14)=5.57, p < 0.05] than WT mice. REMS amounts did not diﬀer
during the ﬁrst 12 h post-injection of LPS, but decreased during the
next 12 h (light period) [Fig. 2E; Treatment: F(1,14)=6.69, p < 0.05]. No
strain diﬀerences were detected in REMS amounts after LPS during the
post-injection light or dark period. NREMS EEG SWA decreased in
both strains following LPS [Treatment: F(1,14)=5.77, p < 0.05], in the
post-injection dark period (not shown). No strain diﬀerences in the
power spectrum 0–2 h post-LPS treatment were found (Fig. 2F).
Fig. 1. IL37tg mice have more spontaneous NREMS and similar sleep rebounds compared to WT mice. NREMS amounts [A], REMS amounts [B] and NREMS EEG SWA [C] in 12 h
periods corresponding to the light or dark phase (gray ﬁll) for WT mice (white bars; n=24) and IL37tg mice (black bars; n=23; ## p < 0.01, WT vs. IL37tg) are shown. NREMS EEG
power [D] during the 12 h light period (ZT0-12) is depicted. After 6 h sleep deprivation, NREMS amounts [E], REMS amounts [F] and NREMS EEG SWA [G] in the subsequent 6 h light
period and 12 h dark period (shaded areas) for WT (n=7) and IL37tg mice (n=9) are expressed as change from baseline values. NREMS EEG power [H] during the 6 h light period
following sleep deprivation (ZT6-12) is reported (all data expressed as mean ± SEM; asterisks indicate within strain, treatment diﬀerences,* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
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4.3. Experiment 3: EEG responses to inﬂuenza challenge
IL37tg mice had more NREMS than WT mice following virus
challenge irrespective of the photoperiod. WT mice had on average
8 min less time in NREMS than their baseline value during each of the
12 h light periods on PI days 2, 4 [data not shown; Treatment:
F(3,71)=11.12, p < 0.001] and 6 (Fig. 3A; 2 h bins displayed).
Conversely, during the light phase IL37tg mice exhibited an average
of 20 min extra NREMS from baseline, which occurred on each of the
PI days 2, 4 and 6 [Strain: F(1,71)=17.25, p < 0.001]. Virus infection
decreased NREMS episode lengths in WT more than in IL37tg mice
[Strain: F(1,71)=9.79, p < 0.01] in the light period (data not shown),
whereas the number of NREMS bouts slightly increased in both strains
[Fig. 3D; Treatment: F(3,71)=3.06, p < 0.05].
The characteristic virus-induced NREMS elevations during the dark
were detected in both strains [Treatment: F(3,71)=5.17, p < 0.01].
During the dark period both strains increased duration of NREMS;
WT mice had on average 41 min extra NREMS and IL37tg mice had
74 min extra NREMS on each of the PI days 2, 4 and 6. The NREMS
increases in the dark period were statistically signiﬁcant from their
respective baseline values on PI days 2 and 6 in WT mice and PI days 4
and 6 in IL37tg mice (baseline and PI day 6 data shown in Fig. 3).
Overall, NREMS episode lengths were longer in IL37tg mice, than in
WT mice [Strain: F(1,71)=8.81, p < 0.01] in the dark. After infection, the
frequency of NREMS bouts in the dark period increased in both strains,
and was signiﬁcant on PI day 6 [Fig. 3D; Treatment: F(3,71)=5.47, p <
0.01].
After inﬂuenza challenge of WT mice, REMS duration decreased in
the light and dark periods (Fig. 3B) compared to their baseline REMS.
In IL37tg mice, attenuated REMS occurred in the light period;
whereas, during the dark period, elevated REMS amounts occurred
in response to virus infection [Treatment: F(3,71)=7.02, p < 0.001]. The
REMS increases during the dark period in IL37tg mice were statisti-
cally signiﬁcant on PI day 4 (not shown). In summary, there were
signiﬁcant decreases from baseline on PI day 6 (light and dark) in WT
mice. IL37tg mice manifested REMS decreases on PI days 4 and 6 in
the light period and increases during PI day 4 in the dark period. In
IL37tg mice, the length of REMS episodes in the light period were
longer after infection on PI day 4 [data not shown; Treatment:
F(3,71)=4.42, p < 0.01] and did not change in WT mice. After viral
Fig. 2. IL37tg mice show attenuated sleep responses to IL-1β and LPS. WT mice (white symbols) and IL37tg mice (black symbols) were IP injected with saline (0.2 ml) just prior to dark
onset and EEG/EMG was recorded for 24 h. Mice (n=7/strain) then received 180 ng of IL-1β [A, B, C] or 500 ng lipopolysaccharide (LPS; n=8/strain; D, E, F) and recording continued.
Duration in state data are presented as diﬀerences from saline in NREMS [A,D] and REMS [B, E] averaged over 12 h periods corresponding to dark and light periods. EEG power spectra
(1–20 Hz) from artifact-free NREMS-scored epochs over the ﬁrst 2 h post-injection (ZT12-14) are depicted [C, F; WT top upper panels, IL37tg bottom panels]. Asterisks indicate within
strain, treatment diﬀerences (* = p < 0.05; ** = p < 0.01) and pound signs indicate diﬀerences between strains (# = p < 0.05; ## = p < 0.01; gray ﬁll indicates dark period).
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challenge the number of REMS bouts decreased in both strains
(Fig. 3E), during the light [Treatment: F(3,71)=5.19, p < 0.01], but only
decreased in WT mice during the dark [Treatment: F(3,71)=3.58, p <
0.05] which was diﬀerent between strains on PI day 6.
During the light period, NREMS EEG SWA post-infection re-
sponses were higher in IL37tg mice whereas they did not change in
WT mice [Fig. 3C; Strain: F(1,71)=17.25, p < 0.001]. The overall strain
diﬀerences for NREMS SWA during the light were statistically sig-
niﬁcant, but these eﬀects for any single PI day were not signiﬁcant.
NREMS spectral content during the light phase showed slight de-
creases from baseline in WT mice [Fig. 3F; Treatment×Hz:
F(19,380)=4.41, p < 0.05], but not in IL37tg mice. In WT mice, the
diﬀerences were signiﬁcant in the 3–6 Hz window. During the dark
period, no signiﬁcant strain or treatment diﬀerences in NREMS EEG
SWA or NREMS power spectra (not shown) were detected.
4.4. Experiment 4: Activity, core body temperature and body weight
after inﬂuenza challenge.
There was attenuated virus-induced morbidity in IL37tg mice
compared to WT mice. The decreased locomotor activity that follows
inﬂuenza infection in WT mice was less pronounced in IL37tg mice
during PI days 3, 4 and 5 [Fig. 4A; Strain×Day: F(6,96)=4.53, p < 0.05].
A hypothermic response to infection was observed on PI days 3–7
[Fig. 4B; Day: F(6,96)=88.27, p < 0.001] in both strains. Although WT
mice temperatures were lower than those of IL37tg mice on post-
inoculation days 3–7, these temperature diﬀerences between strains
were not statistically signiﬁcant after the Huynh–Feldt adjustment
[Fig. 4B; Strain×Day: F(6,96)=2.52, p=0.067]. Inﬂuenza induced de-
creases in body weight were less prominent in IL37tg mice than WT
mice [Fig. 4C; Strain×Day: F(6,96)=4.85, p < 0.05]. Pairwise compar-
isons indicated that WT mice lost 3.28 ± 0.2 and 4.4 ± 0.4 g from
baseline, which was signiﬁcantly diﬀerent from the 2.1 ± 0.5 and 2.8 ±
0.6 g lost in IL37tg mice, on PI days 3 and 4, respectively.
5. Discussion
Sleep responses after the three diﬀerent inﬂammatory challenge
conditions were distinct from each other and in each case the presence
of the IL-37 gene in mice had an eﬀect. In baseline conditions, IL-37
expression in IL37tg mice is low (McNamee et al., 2011; Luo et al.,
2014; Coll-Miro et al., 2016) and baseline sleep was only slightly
increased in IL37tg mice above that of WT mice; the biological
signiﬁcance of the small change is questionable. The reason for the
failure to express IL-37 in the resting state is likely due to the
instability of the sequence as described by Buﬂer et al. (2004), so this
is not unexpected. Similarly, after the short acute 6 h SD, both strains
had NREMS and REMS rebounds and there were no strain diﬀerences.
Several pro-inﬂammatory cytokines, including IL-1β and TNFα, play a
role in sleep responses to SD (reviewed in Besedovsky, Lange and Born,
2012; Davis and Krueger, 2012; Imeri and Opp, 2009; Jewett and
Krueger, 2012). Thus in a variety of species, including humans, chronic
SD is associated with an inﬂammatory response and increases in IL-1β
and TNF expression (Irwin, Olmstead and Carroll, 2016; Vgontzas
Fig. 3. IL37tg mice have enhanced sleep responses to inﬂuenza virus challenge on post infection (PI) day 6.IL37tg mice (n=10) had more NREMS [A] during light and/or dark hours
(shaded areas representing the 12 h dark period) than WT mice (n=12) and their own baseline values. Both strains manifest an increased number of NREMS episodes [D] during the
dark period following viral challenge. REMS amounts [B] during the dark and REMS bout frequency [E] during the light and dark were inhibited in WT mice, but not IL37tg mice after
infection. There were no changes in NREMS EEG SWA in on PI day 6 in either strain regardless of the photoperiod [C]. Power spectra [F] decreased with infection in WT mice but not
IL37tg mice (PI day 6 ZT0-12 shown; *p < 0.05, **p < 0.01, ***p < 0.001, WT baseline vs. PI day 6; +p < 0.05, IL37tg baseline vs. PI day 6 and #p < 0.05, WT vs. IL37tg; statistical
symbols derived from 12 h data analyses; all data expressed as mean ± SEM).
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et al., 2004; Zielinski et al., 2014). In mice, although chronic prolonged
SD enhances sleep-promoting pro-inﬂammatory cytokines, acute 6 h of
SD is associated with small increases in pro-inﬂammatory cytokine
mRNA expression in some parts of the brain, but not in the sleep
regulatory hypothalamus (Dumaine and Ashley, 2015; Zielinski et al.,
2012). Regardless, because the presence of IL-37 attenuates inﬂamma-
tion-induced pro-inﬂammatory cytokine expression in IL37tg mice, it
is possible that the smaller NREMS responses in the IL37tg mice
compared to WT mice, albeit not signiﬁcantly diﬀerent, were the result
of attenuated pro-inﬂammatory responses.
In contrast to the baseline and SD-induced sleep responses, there
were clear and large attenuations of IL-1β- and LPS-induced NREMS
responses. The doses of IL-1β and LPS used in the current experiments
are pro-somnogenic (Davis et al., 2015; Opp et al., 1991; Taishi et al.,
2012). Because IL-1β can induce itself and LPS induces IL-1β and
other pro-inﬂammatory cytokines, one mechanism responsible for the
attenuated IL-1β- or LPS-induced sleep responses is IL-37-mediated
inhibition of pro-inﬂammatory cytokines. That said, higher doses of
either IL-1β (Opp et al., 1991) or LPS (Taishi et al., 2012; Toth and
Opp, 2001) inhibit and/or fragment sleep suggesting that more severe
inﬂammatory conditions can be sleep inhibitory. After the inﬂuenza
virus challenge, although increases in NREMS durations were observed
in both WT and IL37tg mice, it seems likely that the larger increases in
NREMS in IL37tg mice were the result of an attenuation of an
excessive upregulation of pro-inﬂammatory cytokines associated with
the severe infection. This interpretation is consistent with the attenua-
tion of locomotor, weight loss and temperature responses in the IL37tg
mice, although the eﬀects manifest on PI days 3–5 after which the mice
succumbed to the infection and morbidity measures more closely
approximated those of WT mice. Still the transgene seems to confer
some degree of host protection to the extent that measures of morbidity
after virus challenge were of lower magnitude in the IL37tg mice than
in WT mice; this observation is also consistent with prior reports
(Bulau et al., 2014; McNamee et al., 2011; Nold et al., 2010; Slimani
et al., 2014).
Although it has been known for over 10 years that IL-37 binds to
the alpha chain of the IL-18 receptor (IL-18Rα) (Kumar et al., 2002;
Pan et al., 2001), the aﬃnity is markedly low (Kumar et al., 2002) such
that IL-37 is not a receptor antagonist for IL-18Rα (Buﬂer et al., 2002;
Kumar et al., 2002) and therefore cannot account for the anti-
inﬂammatory properties of IL-37. IL-37 also binds to the IL-18 binding
protein (Buﬂer et al., 2002), but this complex also does not function as
a receptor antagonist for IL-18. In the IL37tg mice, the anti-inﬂam-
matory eﬀects on sleep responses to IL-1β, LPS, and inﬂuenza infection
are likely due to the formation of a complex of IL-37 with IL-18Rα and
the co-receptor IL-1R8 (formerly TIR8) (Nold-Petry et al., 2015).
However, the signal is not that of IL-18 but rather an attenuated
signal due to the decoy nature of IL-1R8 (Garlanda et al., 2013a;
2013b). The IL37tg mice are protected against a systemic response to
LPS (Nold et al., 2010), but IL37tg mice deﬁcient in IL-1R8 are not
protected (Nold-Petry et al., 2015). In WT mice, recombinant IL-37 is
eﬀective in suppressing inﬂammation in several mouse models of
inﬂammation, but not in mice deﬁcient in IL-1R8 (Li et al., 2015;
Lunding et al., 2015; Moretti et al., 2014). Although speculative, the
observed responses could occur via the activation of other nonspeciﬁc
pathways in IL37tg mice.
In general, the presence of IL-37 enhances anti-inﬂammatory
cytokine expression and inhibits pro-inﬂammatory cytokines (Sharma
et al., 2008). There are however many nuances to cytokine expression
dynamics and actions. Thus, cytokine regulation and expression are
complex processes occurring over multiple time scales lasting seconds
to hours or even days. These events are mediated, in part, by various
Fig. 4. IL37tg mice are more active, less hypothermic, and have less weight loss than WT mice following viral challenge. Strain diﬀerences in [A] locomotor activity (6 h means ± SEM),
[B] temperature (6 min means and positive SEM for IL37tg and negative SEM for WT) and [C] body weights (daily means and negative SEM) are most apparent on post-infection days
3–5 (#p < 0.05, WT vs. IL37tg; n=9/strain).
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microbial stimuli, cell signaling mechanisms, cleavage enzymes, post-
transcriptional regulation, feedback inhibition, receptors and their
components, and inhibitory cytokines. Further, many cytokines, in-
cluding IL-1β and TNFα have diurnal variations in their expression
inﬂuencing the expression levels of other cytokines. For example, the
cytokine expression of TNFα has an expression pattern that typically
occurs earlier than IL-1β in response to most stimuli, although it is
shorter in duration of expression (Jewett et al., 2015). This is, in part,
reﬂective in the sleep eﬀects found in IL-1β-and TNFα-KO mice or
their respective receptor KO mice where the inhibition of NREMS and
SWA responses in these mice across the day or to somnogenic stimuli
corresponds with these expression timing and duration patterns (Kapás
et al., 2008; Fang et al., 1998; Taishi et al., 1998; 1999). Moreover,
anti-inﬂammatory cytokines such as IL-10 and TGFβ tend to occur
hours after IL-1β and TNFα, in a compensatory action (Toth and Opp,
2001; Kubota et al., 2000; Opp et al., 1995).
Data presented herein also have bearing on the issue of whether
sleep is beneﬁcial for recuperation from microbial challenge. The
current ﬁndings are consistent with earlier work correlating robust
sleep responses to infectious challenge to lower morbidity (Toth et al.,
1993). Similar ﬁndings were reported in bacteria-infected drosophila
that had less sleep rebound after sleep deprivation also had increased
mortality rates (Kuo and Williams, 2014). Similarly, we recently
showed that mice lacking a component of the IL-1 receptor signaling
complex, brain-speciﬁc IL-1 receptor accessory protein, slept less and
had higher mortality after inﬂuenza virus challenge using the same
virus and dose as that used in this report (Davis et al., 2015). The
antithesis also holds in that disrupted sleep, impedes recuperation
(Faraut et al., 2012; Friese et al., 2009; Tang et al., 2009). Regardless,
current data suggesting the larger NREMS responses to viral challenge
occurring in the IL37tg mice aids in recuperation remain correlative,
not causative.
In conclusion, there is a robust literature linking sleep and sleep
loss to host defenses (reviewed Besedovsky et al., 2012; Imeri and Opp,
2009; Toth and Jhaveri, 2003; Zielinski and Krueger, 2011). Indeed,
chronic sleep loss is associated with chronic inﬂammation and acute
sleep loss induces multiple cytokines in brain and systemically and they
are involved in the inﬂammatory processes. Similarly, sleep pathologies
such as insomnia and sleep apnea are accompanied by chronic low-
grade inﬂammation. A separate literature describes the relationships
between severe inﬂammation, induced by microbial products such as
LPS, muramyl peptides, and various viral products such as viral double
stranded RNA to sleep responses (reviewed Majde and Krueger, 2005;
Imeri and Opp, 2009). Current results are consistent with and expand
that literature by suggesting that IL-37 has a role in host protection,
including sleep responses, in response to inﬂammatory challenge.
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